002773 康弘药业
交易中 04-13 14:18:03
资讯
新帖
简况
康弘药业(002773)披露使用8亿元自有资金购买结构性存款公告,4月7日股价下跌0.73%
证券之星 · 04-07
康弘药业(002773)披露使用8亿元自有资金购买结构性存款公告,4月7日股价下跌0.73%
康弘药业:截至2026年3月31日,公司股东户数约为3.93万户
证券之星 · 04-02
康弘药业:截至2026年3月31日,公司股东户数约为3.93万户
异动快报:康弘药业(002773)3月27日10点21分触及涨停板
证券之星 · 03-27
异动快报:康弘药业(002773)3月27日10点21分触及涨停板
长护险全面推行;我国已稳步迈入结核病中低流行国家行列
21世纪经济报道 · 03-27
长护险全面推行;我国已稳步迈入结核病中低流行国家行列
股市必读:康弘药业(002773)3月26日董秘有最新回复
证券之星 · 03-27
股市必读:康弘药业(002773)3月26日董秘有最新回复
康弘药业:KH903项目后续工作开展尚在评估中
证券之星 · 03-26
康弘药业:KH903项目后续工作开展尚在评估中
股市必读:康弘药业(002773)3月16日董秘有最新回复
证券之星 · 03-17
股市必读:康弘药业(002773)3月16日董秘有最新回复
康弘药业公布国际专利申请:“芳基丙酸化合物及其制备方法与用途”
证券之星 · 03-14
康弘药业公布国际专利申请:“芳基丙酸化合物及其制备方法与用途”
康弘药业:公司重视市值管理工作
证券之星 · 03-06
康弘药业:公司重视市值管理工作
康弘药业(002773)披露聘任证券事务代表公告,3月5日股价上涨1.31%
证券之星 · 03-05
康弘药业(002773)披露聘任证券事务代表公告,3月5日股价上涨1.31%
康弘药业(002773)披露国家集采接续采购中选结果,3月2日股价下跌4.07%
证券之星 · 03-02
康弘药业(002773)披露国家集采接续采购中选结果,3月2日股价下跌4.07%
康弘药业最新公告:公司参与的国家组织集采药品协议期满品种接续采购中选结果
证券之星 · 03-01
康弘药业最新公告:公司参与的国家组织集采药品协议期满品种接续采购中选结果
康弘药业(002773)披露收到药物临床试验批准通知书,2月25日股价上涨1.46%
证券之星 · 02-25
康弘药业(002773)披露收到药物临床试验批准通知书,2月25日股价上涨1.46%
康弘药业(002773.SZ):KHN707片获准开展用于失眠症临床试验
智通财经 · 02-25
康弘药业(002773.SZ):KHN707片获准开展用于失眠症临床试验
康弘药业:截至2026年1月30日,公司股东户数约为3.45万户
证券之星 · 02-03
康弘药业:截至2026年1月30日,公司股东户数约为3.45万户
股市必读:康弘药业(002773)1月23日董秘有最新回复
证券之星 · 01-26
股市必读:康弘药业(002773)1月23日董秘有最新回复
康弘药业:KH110项目Ⅲ期临床试验正在全国多家医院开展
证券之星 · 01-23
康弘药业:KH110项目Ⅲ期临床试验正在全国多家医院开展
信达证券:首次覆盖康弘药业给予买入评级
证券之星 · 01-20
信达证券:首次覆盖康弘药业给予买入评级
康弘药业(002773.SZ):度普利尤单抗KH816注射液药物临床试验获批
智通财经网 · 01-14
康弘药业(002773.SZ):度普利尤单抗KH816注射液药物临床试验获批
康弘药业:截至2026年1月9日股东户数为33,118户
证券之星 · 01-12
康弘药业:截至2026年1月9日股东户数为33,118户
加载更多
公司概况
公司名称:
成都康弘药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2015-06-26
主营业务:
成都康弘药业集团股份有限公司的主营业务是药品(包括生物制品、中成药、化学药)和医疗器械(主要是眼科医疗器械)的研发、生产与销售。公司的主要产品是康柏西普眼用注射液、利非司特滴眼液、普拉洛芬滴眼液、舒肝解郁胶囊、松龄血脉康胶囊、渴络欣胶囊、胆舒胶囊、一清胶囊、盐酸文拉法辛缓释片、阿立哌唑口崩片、阿立哌唑口服溶液、氢溴酸伏硫西汀片、草酸艾司西酞普兰片、草酸艾司西酞普兰口服溶液、枸橼酸莫沙必利片、枸橼酸莫沙必利分散片、盐酸普拉克索缓释片、右佐匹克隆片等药品和医疗器械。
发行价格:
13.62
{"stockData":{"symbol":"002773","market":"SZ","secType":"STK","nameCN":"康弘药业","latestPrice":27.85,"timestamp":1776061083000,"preClose":28.05,"halted":0,"volume":7920337,"delay":0,"changeRate":-0.0071,"floatShares":687000000,"shares":921000000,"eps":1.3573,"marketStatus":"交易中","change":-0.2,"latestTime":"04-13 14:18:03","open":28,"high":28.29,"low":27.4,"amount":220000000,"amplitude":0.0317,"askPrice":27.86,"askSize":20,"bidPrice":27.85,"bidSize":54,"shortable":0,"etf":0,"ttmEps":1.3573,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1776063600000},"marketStatusCode":2,"adr":0,"adjPreClose":28.05,"symbolType":"stock","openAndCloseTimeList":[[1776043800000,1776051000000],[1776056400000,1776063600000]],"highLimit":30.86,"lowLimit":25.25,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":921320954,"isCdr":false,"pbRate":2.82,"roa":"--","peRate":20.518677,"roe":"11.55%","epsLYR":1.3,"committee":0.794721,"marketValue":25659000000,"turnoverRate":0.0115,"status":1,"floatMarketCap":19128000000},"requestUrl":"/m/hq/s/002773","defaultTab":"news","newsList":[{"id":"2625120931","title":"康弘药业(002773)披露使用8亿元自有资金购买结构性存款公告,4月7日股价下跌0.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625120931","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625120931?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:13","pubTimestamp":1775556796,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘,康弘药业报收于28.43元,较前一交易日下跌0.73%,最新总市值为261.93亿元。该股当日开盘28.63元,最高29.07元,最低27.92元,成交额达3.45亿元,换手率为1.77%。近日,康弘药业披露《关于使用自有资金购买理财产品的公告》。公告显示,公司使用闲置自有资金8亿元人民币,向中国银行成都武侯支行购买了名为“人民币结构性存款”的保本浮动收益型理财产品,产品期限为47天,自2026年4月3日起算,到期日为2026年5月20日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700025189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0197","BK0239","LU1064130708.USD","LU2148510915.USD","LU1064131003.USD","002773"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624649575","title":"康弘药业:截至2026年3月31日,公司股东户数约为3.93万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2624649575","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624649575?lang=zh_cn&edition=full","pubTime":"2026-04-02 15:06","pubTimestamp":1775113581,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)04月02日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘你好,请问截止至2026年3月31日收盘公司股东人数为多少,谢谢!康弘药业回复:尊敬的投资者,您好!截至2026年3月31日,公司股东户数约为3.93万户。感谢您的关注与支持!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200019194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","002773","BK0196","LU1064131003.USD","BK0197","BK0239","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622816415","title":"异动快报:康弘药业(002773)3月27日10点21分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2622816415","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622816415?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:25","pubTimestamp":1774578325,"startTime":"0","endTime":"0","summary":"证券之星3月27日盘中消息,10点21分康弘药业触及涨停板。其所属行业生物制品目前上涨。领涨股为欧林生物。该股为创新药,阿尔茨海默病,化学原料药概念热股,当日创新药概念上涨3.16%,阿尔茨海默病概念上涨3.15%,化学原料药概念上涨2.55%。3月26日的资金流向数据方面,主力资金净流入13.53万元,占总成交额0.13%,游资资金净流出1024.51万元,占总成交额9.58%,散户资金净流入1010.98万元,占总成交额9.46%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700017169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0196","002773","LU2148510915.USD","LU1064130708.USD","BK0239","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622157858","title":"长护险全面推行;我国已稳步迈入结核病中低流行国家行列","url":"https://stock-news.laohu8.com/highlight/detail?id=2622157858","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622157858?lang=zh_cn&edition=full","pubTime":"2026-03-27 09:31","pubTimestamp":1774575097,"startTime":"0","endTime":"0","summary":"政策动向8部门印发《加快建立长期护理保险制度实施方案》3月26日,国家医保局、民政部、财政部、人力资源社会保障部、农业农村部、国家卫生健康委、国家税务总局、中国残疾人联合会今日印发《加快建立长期护理保险制度实施方案》。单位职工参加长期护理保险由用人单位和职工个人共同缴费,与职工基本医疗保险费共同缴纳。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603273686638836.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273686638836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0197","000513","LU1064130708.USD","BK4077","BK4231","BK4563","BK0187","BK0196","BK0239","ADC","LU2148510915.USD","002773","SY","BK4080","BK4503","BK0028","BK0188","300497","LU1064131003.USD","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622952895","title":"股市必读:康弘药业(002773)3月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2622952895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622952895?lang=zh_cn&edition=full","pubTime":"2026-03-27 03:27","pubTimestamp":1774553230,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘,康弘药业报收于25.14元,下跌1.49%,换手率0.61%,成交量4.2万手,成交额1.07亿元。董秘最新回复投资者: 您好!请问KH903管线肿瘤创新药是否仍在正常推进?KH903项目后续工作开展尚在评估中,暂未启动题述项目的临床Ⅲ期试验,后续进展请关注公司相关动态。来自公司公告汇总:子公司获临床试验批件,注射用KHN922拟用于晚期实体瘤治疗,具备双载荷抗体偶联技术特征。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700006210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","002773","BK0197","LU1064131003.USD","BK0239","LU1064130708.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622889495","title":"康弘药业:KH903项目后续工作开展尚在评估中","url":"https://stock-news.laohu8.com/highlight/detail?id=2622889495","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622889495?lang=zh_cn&edition=full","pubTime":"2026-03-26 09:12","pubTimestamp":1774487528,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业03月26日在投资者关系平台上答复投资者关心的问题。请问KH903管线肿瘤创新药是否仍在正常推进?2024年完成临床2期后,迟迟不见消息,官网“研发动态”也将KH903撤下。KH903项目后续工作开展尚在评估中,暂未启动题述项目的临床Ⅲ期试验,后续进展请关注公司相关动态。药品从研发、临床试验、审评和审批的结果以及时间都具有一定的不确定性,敬请谨慎决策,注意投资风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600010215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","LU1064130708.USD","BK0197","LU2148510915.USD","LU1064131003.USD","002773"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620493100","title":"股市必读:康弘药业(002773)3月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2620493100","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620493100?lang=zh_cn&edition=full","pubTime":"2026-03-17 02:12","pubTimestamp":1773684733,"startTime":"0","endTime":"0","summary":"截至2026年3月16日收盘,康弘药业报收于27.66元,上涨0.69%,换手率0.51%,成交量3.52万手,成交额9670.67万元。董秘最新回复投资者: 公司的股性太死,25年分红会不会考虑转股?公司将根据相关规定和公司实际经营情况,合理安排分红。如有涉及利润分配或资本公积转增股本等相关计划,公司将及时履行信息披露义务并与投资者保持沟通。当日关注点来自交易信息汇总:3月16日主力与游资资金均呈净流出,散户资金净流入187.69万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700001782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064130708.USD","BK0196","002773","BK0239","BK0197","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619458941","title":"康弘药业公布国际专利申请:“芳基丙酸化合物及其制备方法与用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2619458941","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619458941?lang=zh_cn&edition=full","pubTime":"2026-03-14 05:40","pubTimestamp":1773438037,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示康弘药业(002773)公布了一项国际专利申请,专利名为“芳基丙酸化合物及其制备方法与用途”,专利申请号为PCT/CN2025/118927,国际公布日为2026年3月12日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来康弘药业已公布的国际专利申请4个,较去年同期增加了300%。结合公司2025年中报财务数据,2025上半年公司在研发方面投入了2.15亿元,同比增11.27%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031400003844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","LU1064130708.USD","BK0196","BK0197","LU1064131003.USD","LU2148510915.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617768914","title":"康弘药业:公司重视市值管理工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2617768914","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617768914?lang=zh_cn&edition=full","pubTime":"2026-03-06 17:54","pubTimestamp":1772790847,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)03月06日在投资者关系平台上答复投资者关心的问题。投资者提问:你们公司到底有没有在做好市值管理工作?康弘药业回复:尊敬的投资者,您好!公司重视市值管理工作,持续聚焦主业发展,与投资者共享公司发展成果。感谢您的关注与支持!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600029489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","BK0197","BK0196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617250195","title":"康弘药业(002773)披露聘任证券事务代表公告,3月5日股价上涨1.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617250195","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617250195?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:38","pubTimestamp":1772721498,"startTime":"0","endTime":"0","summary":"截至2026年3月5日收盘,康弘药业报收于27.06元,较前一交易日上涨1.31%,最新总市值为249.31亿元。近日,成都康弘药业集团股份有限公司召开第八届董事会第十六次会议,审议通过《关于聘任公司证券事务代表的议案》,同意聘任王婷女士为公司证券事务代表,任期自董事会审议通过之日起至第八届董事会任期届满之日止。王婷女士持有深圳证券交易所颁发的董事会秘书资格证书,具备相应任职资格。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500039643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","LU1064131003.USD","BK0239","LU2148510915.USD","BK0196","161027","LU1064130708.USD","002773"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616380519","title":"康弘药业(002773)披露国家集采接续采购中选结果,3月2日股价下跌4.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616380519","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616380519?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:41","pubTimestamp":1772444463,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘,康弘药业报收于28.05元,较前一交易日下跌4.07%,最新总市值为258.43亿元。近日,康弘药业发布《关于公司参与国家组织集采药品协议期满品种接续采购中选结果的公告》。公告显示,公司参与国家组织集采药品协议期满品种接续采购,枸橼酸莫沙必利片、右佐匹克隆片、盐酸文拉法辛缓释片、阿立哌唑口崩片、草酸艾司西酞普兰片、盐酸普拉克索缓释片、富马酸喹硫平片、玻璃酸钠滴眼液八个产品中标。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200026415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064130708.USD","BK0196","002773","BK0239","BK0197","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616382619","title":"康弘药业最新公告:公司参与的国家组织集采药品协议期满品种接续采购中选结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2616382619","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616382619?lang=zh_cn&edition=full","pubTime":"2026-03-01 16:30","pubTimestamp":1772353827,"startTime":"0","endTime":"0","summary":"康弘药业公告称,公司参加了国家组织集采药品协议期满品种接续采购,公司的枸橼酸莫沙必利片、右佐匹克隆片、盐酸文拉法辛缓释片、阿立哌唑口崩片、草酸艾司西酞普兰片、盐酸普拉克索缓释片、富马酸喹硫平片、玻璃酸钠滴眼液八个产品被接续采购办公室列入中选结果表。采购周期内,医疗机构将优先使用中选药品并确保完成约定采购量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100004434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU2148510915.USD","BK0239","LU1064131003.USD","002773","BK0197","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614356990","title":"康弘药业(002773)披露收到药物临床试验批准通知书,2月25日股价上涨1.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614356990","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614356990?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:33","pubTimestamp":1772029996,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘,康弘药业报收于29.24元,较前一交易日上涨1.46%,最新总市值为269.39亿元。该股当日开盘28.9元,最高29.25元,最低28.74元,成交额达1.24亿元,换手率为0.62%。近日,成都康弘药业集团股份有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》,同意公司自主研发的KHN707片开展用于失眠症的临床试验。该药品后续研发、临床试验、审评审批结果及时间存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500038238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU1064131003.USD","LU1064130708.USD","002773","BK0239","BK0197","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614707790","title":"康弘药业(002773.SZ):KHN707片获准开展用于失眠症临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2614707790","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614707790?lang=zh_cn&edition=full","pubTime":"2026-02-25 17:54","pubTimestamp":1772013268,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业(002773.SZ)公告,公司收到国家药品监督管理局签发的《药物临床试验批准通知书》,相关药物为KHN707片,将开展用于失眠症的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","LU1064131003.USD","LU1064130708.USD","002773","BK0239","BK0197","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608267508","title":"康弘药业:截至2026年1月30日,公司股东户数约为3.45万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2608267508","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608267508?lang=zh_cn&edition=full","pubTime":"2026-02-03 16:57","pubTimestamp":1770109033,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)02月03日在投资者关系平台上答复投资者关心的问题。投资者提问:请问最近的股东人数是多少?康弘药业回复:尊敬的投资者,您好!截至2026年1月30日,公司股东户数约为3.45万户。感谢您的关注与支持!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300028575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","002773","BK0239","BK0196","LU2148510915.USD","BK0197","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606265151","title":"股市必读:康弘药业(002773)1月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606265151","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606265151?lang=zh_cn&edition=full","pubTime":"2026-01-26 03:22","pubTimestamp":1769368930,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘,康弘药业报收于32.58元,上涨1.65%,换手率1.36%,成交量9.34万手,成交额3.03亿元。目前该项目Ⅲ期临床试验正在全国多家医院开展,招募对象为50-80岁的轻、中度阿尔茨海默病患者。相关试验信息已按国家要求登记并公开于国家药品监督管理局“药物临床试验登记与信息公开平台”。当日关注点来自交易信息汇总:1月23日主力资金净流入209.18万元,显示主力小幅加仓。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600001491.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","002773","LU1064130708.USD","BK0196","LU2148510915.USD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605428108","title":"康弘药业:KH110项目Ⅲ期临床试验正在全国多家医院开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2605428108","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605428108?lang=zh_cn&edition=full","pubTime":"2026-01-23 11:45","pubTimestamp":1769139906,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业01月23日在投资者关系平台上答复投资者关心的问题。感谢您对公司KH110项目的关注。目前该项目Ⅲ期临床试验正在全国多家医院开展,招募对象为50-80岁的轻、中度阿尔茨海默病患者。相关试验信息已按国家要求登记并公开于国家药品监督管理局“药物临床试验登记与信息公开平台”。如您或相关人员有意向参与,建议通过该平台进一步了解具体入组标准,并前往就近的研究医院进行评估。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300016289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064130708.USD","BK0196","002773","BK0239","BK0197","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604159574","title":"信达证券:首次覆盖康弘药业给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2604159574","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604159574?lang=zh_cn&edition=full","pubTime":"2026-01-20 07:36","pubTimestamp":1768865760,"startTime":"0","endTime":"0","summary":"信达证券股份有限公司唐爱金近期对康弘药业进行研究并发布了研究报告《公司首次覆盖报告:深耕眼科黄金赛道,基因治疗创新管线打开新空间》,首次覆盖康弘药业给予买入评级。康弘药业(00277 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260120/c674141365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["002773","601059"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603692701","title":"康弘药业(002773.SZ):度普利尤单抗KH816注射液药物临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2603692701","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603692701?lang=zh_cn&edition=full","pubTime":"2026-01-14 18:47","pubTimestamp":1768387646,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业 发布公告,近日,公司全资子公司成都康弘生物科技有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》,该药品名称:KH816注射液。KH816注射液是康弘生物研发的度普利尤单抗生物类似药。度普利尤单抗通过I型受体抑制IL-4信号传导,并通过II型受体抑制IL-4和IL-13信号传导。利用度普利尤单抗阻断IL-4Rα,可抑制IL-4和IL-13细胞因子诱导的炎性反应,包括促炎细胞因子、趋化因子、一氧化氮和IgE释放。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康弘药业(002773.SZ):度普利尤单抗KH816注射液药物临床试验获批","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0196","LU2148510915.USD","LU1064131003.USD","BK0197","BK0239","LU1064130708.USD","002773"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602356930","title":"康弘药业:截至2026年1月9日股东户数为33,118户","url":"https://stock-news.laohu8.com/highlight/detail?id=2602356930","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602356930?lang=zh_cn&edition=full","pubTime":"2026-01-12 09:00","pubTimestamp":1768179650,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)01月12日在投资者关系平台上答复投资者关心的问题。投资者提问:股东人数怎么还不更新啊?截止20260年1月8号,股东人数是多少呢?康弘药业回复:尊敬的投资者,您好!截至2026年1月9日,公司股东户数为33,118户。感谢您的关注与支持!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200002004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0239","BK0196","LU1064131003.USD","002773","LU1064130708.USD","BK0197"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776061090516,"stockEarnings":[{"period":"1week","weight":-0.0206},{"period":"1month","weight":0.005},{"period":"3month","weight":-0.1829},{"period":"6month","weight":-0.221},{"period":"1year","weight":0.1221},{"period":"ytd","weight":-0.0641}],"compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":-0.0356},{"period":"3month","weight":-0.0326},{"period":"6month","weight":0.0229},{"period":"1year","weight":0.2366},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都康弘药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"39300人(较上一季度增加16.62%)","perCapita":"17476股","listingDate":"2015-06-26","address":"四川省成都市金牛区蜀西路108号","registeredCapital":"92132万元","survey":" 成都康弘药业集团股份有限公司的主营业务是药品(包括生物制品、中成药、化学药)和医疗器械(主要是眼科医疗器械)的研发、生产与销售。公司的主要产品是康柏西普眼用注射液、利非司特滴眼液、普拉洛芬滴眼液、舒肝解郁胶囊、松龄血脉康胶囊、渴络欣胶囊、胆舒胶囊、一清胶囊、盐酸文拉法辛缓释片、阿立哌唑口崩片、阿立哌唑口服溶液、氢溴酸伏硫西汀片、草酸艾司西酞普兰片、草酸艾司西酞普兰口服溶液、枸橼酸莫沙必利片、枸橼酸莫沙必利分散片、盐酸普拉克索缓释片、右佐匹克隆片等药品和医疗器械。","listedPrice":13.62},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康弘药业(002773)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康弘药业,002773,康弘药业股票,康弘药业股票老虎,康弘药业股票老虎国际,康弘药业行情,康弘药业股票行情,康弘药业股价,康弘药业股市,康弘药业股票价格,康弘药业股票交易,康弘药业股票购买,康弘药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康弘药业(002773)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}